Beijing Hotgen Biotech Past Earnings Performance
Past criteria checks 0/6
Beijing Hotgen Biotech has been growing earnings at an average annual rate of 8.4%, while the Life Sciences industry saw earnings growing at 21.9% annually. Revenues have been declining at an average rate of 40.3% per year.
Key information
8.4%
Earnings growth rate
8.2%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | -40.3% |
| Return on equity | -1.1% |
| Net Margin | -5.8% |
| Next Earnings Update | 30 Aug 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Beijing Hotgen Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 454 | -26 | 248 | 120 |
| 31 Dec 23 | 541 | 27 | 250 | 131 |
| 30 Sep 23 | 954 | -102 | 351 | 152 |
| 30 Jun 23 | 1,818 | 215 | 448 | 177 |
| 31 Mar 23 | 2,395 | 398 | 460 | 179 |
| 31 Dec 22 | 3,557 | 945 | 495 | 191 |
| 30 Sep 22 | 4,583 | 1,811 | 421 | 187 |
| 30 Jun 22 | 3,815 | 1,548 | 324 | 153 |
| 31 Mar 22 | 5,506 | 2,190 | 413 | 160 |
| 31 Dec 21 | 5,369 | 2,186 | 405 | 132 |
| 30 Sep 21 | 4,164 | 1,583 | 379 | 104 |
| 30 Jun 21 | 4,023 | 1,563 | 347 | 91 |
| 31 Mar 21 | 1,703 | 713 | 230 | 57 |
| 31 Dec 20 | 514 | 112 | 163 | 48 |
| 30 Sep 20 | 218 | 26 | 113 | 34 |
| 30 Jun 20 | 206 | 24 | 106 | 32 |
| 31 Mar 20 | 212 | 36 | 98 | 31 |
| 31 Dec 19 | 210 | 34 | 98 | 29 |
| 30 Sep 19 | 203 | 43 | 87 | 25 |
| 31 Dec 18 | 187 | 48 | 76 | 18 |
| 31 Dec 17 | 142 | 30 | 59 | 14 |
| 31 Dec 16 | 122 | 29 | 48 | 13 |
Quality Earnings: 688068 is currently unprofitable.
Growing Profit Margin: 688068 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688068 is unprofitable, but has reduced losses over the past 5 years at a rate of 8.4% per year.
Accelerating Growth: Unable to compare 688068's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 688068 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (0.7%).
Return on Equity
High ROE: 688068 has a negative Return on Equity (-1.14%), as it is currently unprofitable.